Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Exelixis history
Exelixis company history timeline
Exelixis was founded in 1994; the scientific founders were Spyridon Artavanis–Tsakonas, at Yale at that time, and Corey Goodman and Gerry Rubin who were then at the University of California, Berkeley.
George Scangos joined the company as CEO in 1996.
By 2000 it had left the radical exploratory phase behind and became focused on drug discovery and had a chemical library of 4 million compounds.
By 2002 the company had limited its internal efforts to cancer, and had settled its strategy on discovering and developing drugs that could inhibit targeted small sets of tyrosine kinases that are needed for cancer formation, growth, and metastasis.
In 2006 Exelixis partnered with Daiichi Sankyo on compounds that targeted mineralocorticoid receptors; esaxerenone was part of this collaboration.
In 2007, the company partnered its MEK inhibitor program with Genentech; cobimetinib (at that time XL-518) was part of this collaboration.
At ASCO 2012, Exelixis presents results from the phase 1b study evaluating cabozantinib in patients with advanced renal cell carcinoma (RCC).
Exelixis' first drug approval came in 2012, when cabozantinib was approved for medullary thyroid cancer, an orphan indication.
In 2015 Genentech and Exelixis won FDA approval for cobimetinib for certain forms of melanoma.
In March 2016 Exelixis licensed to Ipsen worldwide rights (outside the US, Canada, and Japan) to market cabozantinib.
In April 2016 the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.
Rate how well Exelixis lives up to its initial vision.
Exelixis jobs
Do you work at Exelixis?
Does Exelixis communicate its history to new hires?
Exelixis competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gilead Sciences | 1987 | $28.8B | 11,800 | 766 |
| Regeneron | 1988 | $14.2B | 9,123 | 346 |
| Merck | 1891 | $64.2B | 74,000 | 2,469 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 114 |
| Sarepta Therapeutics | 1980 | $1.9B | 840 | 26 |
| Seagen | 1997 | $2.0B | 900 | - |
| Acadia Pharmaceuticals | 1993 | $957.8M | 570 | 107 |
| Alnylam Pharmaceuticals | 2002 | $2.2B | 1,323 | - |
| Zoetis | 1952 | $9.3B | 11,300 | 242 |
| Intarcia Therapeutics | 1995 | $70.0M | 44 | - |
Exelixis history FAQs
Zippia gives an in-depth look into the details of Exelixis, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Exelixis. The employee data is based on information from people who have self-reported their past or current employments at Exelixis. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Exelixis. The data presented on this page does not represent the view of Exelixis and its employees or that of Zippia.
Exelixis may also be known as or be related to EXELIXIS INC, Exelixis, Exelixis Inc, Exelixis Pharmaceuticals, Inc. (1994-2000) and Exelixis, Inc.